Transient injection site reaction to alirocumab during immune system activation: a case series. Issue 5 (5th May 2022)

• Record Type: Journal Article
• Authors: Bär, Sarah; Räber, Irene; Koskinas, Konstantinos C.; Schlapbach, Christoph; Räber, Lorenz
• Editors: Oxborough, David; Hartley, Adam; Khan, Tina; Amin, Reshma; Kott, Katharine
• Is Part Of: European heart journal. Volume 6:Issue 5(2022)
• Publication Date: 2022-05-05
• Subjects: PCSK9 inhibitor -- Alirocumab -- Injection site reaction -- Inflammation -- Case report; Cardiology -- Periodicals; Cardiology -- Case studies -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Case studies -- Periodicals; 616.12
• DOI: 10.1093/ehjcr/ytac187
• Languages: English
• ISSNs: 2514-2119

Abstract

Abstract: Background: Injection site reactions (ISRs) are known side effects of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor alirocumab. Transient ISR to alirocumab after a long phase of good tolerability have not been reported previously. Case summary: A 55-year-old woman (Patient 1) and a 77-year-old man (Patient 2) were treated with alirocumab for the management of dyslipidaemia. Both patients tolerated the treatment without side effects for 7 and 2 months, respectively. After an upper respiratory tract infection in Patient 1 and a first COVID-19 vaccination in Patient 2, both patients suddenly developed ISR with erythema, calor, and itching upon 2 (Patient 1) and 1 (Patient 2) subsequent injection(s), respectively. Symptoms resolved with local steroids, oral antihistamines, and cooling. After termination of the presumed immune system activated state, alirocumab was well tolerated again in both patients without recurrence of any ISR upon repeated applications. Discussion: These are the first cases to report transient ISR to a PCSK9 inhibitor, possibly triggered by activation of the immune system, after prolonged good tolerability. Based on the transient and benign nature of the reaction, such patients should be encouraged to continue supervised treatment, as tolerability may return after resolution of the pro-inflammatory state. Graphical Abstract: Graphical abstract ISR, injection site reaction.